The present disclosure relates generally to a photon density wave system, and, more particularly, to apparatus of a transmission mode photon density wave system.
This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present disclosure, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of the various aspects of the present disclosure. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.
Pulse oximetry may be defined as a non-invasive technique that facilitates monitoring of a patient's blood flow characteristics. For example, pulse oximetry may be used to measure blood oxygen saturation of hemoglobin in a patient's arterial blood and/or the patient's heart rate. Specifically, these blood flow characteristic measurements may be acquired using a non-invasive sensor that passes light through a portion of a patient's tissue and photo-electrically senses the absorption and scattering of the light through the tissue. Typical pulse oximetry technology currently utilizes two light emitting diodes (LEDs) and a single optical detector to measure pulse and oxygen saturation of a given tissue bed.
A typical signal resulting from the sensed light may be referred to as a plethysmographic waveform. Such measurements are largely based on absorption of emitted light by specific types of blood constituents. Once acquired, this measurement may be used with various algorithms to estimate a relative amount of blood constituent in the tissue. For example, such measurements may provide a ratio of oxygenated to deoxygenated hemoglobin in the volume being monitored. It should be noted that the amount of arterial blood in the tissue is generally time varying during a cardiac cycle, which is reflected in the plethysmographic waveform.
The accuracy of blood flow characteristic estimation via pulse oximetry depends on a number of factors. For example, variations in light absorption characteristics can affect accuracy depending on where the sensor is located and/or the physiology of the patient being monitored. Additionally, various types of noise and interference can create inaccuracies. For example, electrical noise, physiological noise, and other interference can contribute to inaccurate blood flow characteristic estimates. Some sources of noise are consistent, predictable, and/or minimal, while some sources of noise are erratic and cause major interruptions in the accuracy of blood flow characteristic measurements. Accordingly, it is desirable to enable more accurate and/or controlled measurement of physiologic parameters by providing a system and method that addresses inconsistencies in physiologic characteristics of patients and issues relating to noise.
Advantages of the disclosed techniques may become apparent upon reading the following detailed description and upon reference to the drawings in which:
One or more specific embodiments of the present techniques will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.
Present embodiments relate to non-invasively measuring physiologic parameters corresponding to blood flow in a patient by emitting light into a patient's tissue with light emitters (e.g., lasers/LEDs) and photoelectrically detecting the light after it has passed through the patient's tissue. More specifically, present embodiments are directed to modulate the emitted light at high frequencies to generate resolvable photon density waves. Photon density waves may be described as progressively decaying waves of intensity. On a microscopic level, photons generated by a light source generally make random migrations in a scattering medium. However, the photons collectively form a photon density wave at a modulation frequency that moves away from the light source. Photon propagation is generally dictated by scattering and absorption in the medium through which the waves are moving. Like other waves, photon density waves undergo refraction, diffraction, interference, dispersion, attenuation, and so forth.
Phase changes and amplitude changes in the photon density waves after passing through a medium may be detected to facilitate measurement of changes in total scattering particles and absorber concentration, respectively, in the observed medium. Indeed, the phase of such waves may be sensitive to scattering and the amplitude of such waves may be sensitive to absorption. For example, detection of phase changes in the photon density waves generated by modulation at high frequency may correspond to total hemoglobin because the wavelength of the photon density waves may be shorter than an average absorption length of photons. Thus, detected variations in the phase may be predominantly due to the scattering coefficient and not absorption. In other words, the variation in phase may be predominantly due to the total number of scattering particles (e.g., total hemoglobin) in the observed medium and not merely a ratio of particles (e.g., oxygenated and deoxygenated hemoglobin) that absorb different colors of light. On the other hand, changes in the amplitude of the photon density waves may correspond to absorption of specific light color (e.g. red or infrared light) in the observed volume, and, thus, a ratio of different types of particles (e.g., oxygenated and deoxygenated hemoglobin) in the probed medium.
In addition to the features set forth above, it should also be noted that present embodiments may relate to emitting multiple high frequency photon density waves in coordination with one another to focus on certain tissue areas (e.g., regions rich with pulsatile signals), to facilitate identification of noise artifacts, to address patient specific tissue characteristics (e.g., skin color and low blood oxygen saturation levels), and/or to reduce noise in general. For example, multiple photon density waves may be emitted in patterns such that the waves build on one another to focus intensity at certain points throughout a tissue bed. In a specific example, a tissue bed may be swept with combinations of emission frequencies to identify areas rich with pulsatile signals. Similarly, waves may be emitted such that the waves cancel one another out in a substantially noise-free environment. Thus, detection of the waves that have not been canceled out may be indicative of the presence of noise. Additionally, relative measurements may be utilized to identify and/or correct noise. For example, certain wave features may be detected at multiple detector locations and compared to one another to identify characteristics such as venous pulsation noise.
As generally indicated above, the system 10 may generate and detect light waves to facilitate non-invasive measurement of a patient's physiological characteristics. In embodiments, the system 10 may generate resolvable photon density waves and make relative measurements of certain detected wave characteristics after the waves have been transmitted from one side of a medium (e.g., the tissue of a patient's finger) to the other. The wave characteristics that may be measured in accordance with present embodiments may include characteristics that relate predominantly to absorption of the emitted light in the probed medium (e.g., amplitude change) and characteristics that relate predominantly to scattering in the probed medium (e.g., phase shift). It should be noted that, as will be discussed further below, the correlation of certain wave characteristic (e.g., amplitude and phase) measurements to certain medium characteristics (e.g., quantity of scattering particles and blood oxygen saturation) may be based on high frequency modulation of the system's light sources, which generate the resolvable photon density waves.
As indicated above, the system 10 may be utilized to make measurements that relate predominantly to scattering in the observed volume. More specifically, the system 10 may be utilized to make measurements relating to a total amount of scattering particles in the observed volume based on phase shifts detected in the emitted light waves. For example, the system 10 may emit light that is modulated at a high frequency (e.g., 50 MHz to 3.0 GHz) to generate resolvable photon density waves, and then measure the phase shift of these high frequency waves to facilitate estimation of a total number of scattering particles in the observed medium. Similarly, as set forth above, the system 10 may be utilized to make measurements that relate predominantly to absorption in an observed volume. For example, the system 10 may detect changes in AC and DC amplitudes of the resolvable photon density waves to facilitate detection of a ratio of certain constituents in the blood (e.g., a ratio of oxygenated hemoglobin to total hemoglobin). It should be noted that the amplitude changes and phase shifts measured at a detection point may be considered relative to one or more points. For example, the amplitude and phase shifts measured at a detector may be considered relative to the associated values generated at the emitter.
The functional components disposed within or included as features of the monitor 12 may include sensor driving circuitry 32, an emitter 34, a detector 36, phase detection circuitry 38, and digital signal processing (DSP) circuitry 40. While some embodiments may include differing component arrangements (e.g., certain features may be included in the sensor 14 instead of the monitor 12), including these functional components within the monitor 12 may leave the sensor 14 to be generally composed of fiber optics, which may make the sensor 14 cheap and easily disposable. Indeed, the sensor 14 may include a sensor body 42 that houses fiber optic components 44 and/or portions of the emitter-side fiber optic cable 22 and the detector-side fiber optic cable 30. The fiber optic components 44 may include features (e.g., fiber optic curves and coupling mechanisms) that may facilitate communicative coupling with monitor 12 and/or arranging the emission and detection points of the emitter-side fiber optic cable 22 and the detector-side fiber optic cable 30 generally opposite one another and such that light is emitted substantially directly into the patient's tissue and detected opposite the emission point. As illustrated in
In operation, the driving circuitry 32 may generate waves (e.g., sine waves) and provide timing control signals such that the emitter 34 is activated in specified intervals and/or such that certain varying amplitudes of light are emitted by the emitter 34 to produce desired qualities of the photon density waves. The driving circuitry 32 may also include features that are capable of controlling access to the phase detection circuitry 38 via clock signals provided to the phase detection circuitry 38 from the driving circuitry 32. As an example of a typical process in accordance with present embodiments, the driving circuitry 32 may cause the emitter 34 to emit photon density waves at a high frequency into the emitter-side fiber optic cable 22 such that the photon density waves are transmitted into one side of the patient's tissue 24 and out of the other side of the patient's tissue 26. The detector-side fiber optic cable 30 may receive at least a portion of the photon density waves and transmit the photon density waves to the detector 36, which communicates with the phase detection circuitry 38 to identify phase information and so forth. This information may then be transmitted to the DSP circuitry 40 for analysis. It should be noted that in some embodiments, multiple emitters may be utilized in conjunction with multiple fiber optic cables or the multiple emitters may share a single fiber optic cable.
In some embodiments, in addition to the emitter 50 and the detector 54, the sensor assembly or body 20 may also contain various other features in accordance with present embodiments. For example, the sensor 14 may include a phase detector 58 capable of detecting phase shifts in photon density waves observed by the detector 54. While the phase detection feature 58 is positioned within the sensor assembly 20 in the illustrated embodiment, in some embodiments, the phase detection feature 58 may be located within the oximeter 12. Additionally, the sensor 14 may include an encoder 60 (e.g., a resistor or chip) which may be capable of providing signals indicative of the wavelength(s) of light received from the emitter 50 to allow the oximeter 12 to select appropriate calibration coefficients for calculating oxygen saturation. The data or signal from the encoder 60 may be decoded by a detector/decoder feature 62 in the oximeter 12.
In some embodiments, the oximeter 12 may include a microprocessor 64 coupled to an internal bus 66. Also connected to the bus 66 may be a memory 68 (e.g., RAM and/or ROM) and a display 70. Received signals from the detector 54 may be passed through a first amplifier 72, a switch 74, an analog multiplier 76, a low pass filter 78, and/or an analog-to-digital converter 80. The digital data may then be stored in a queued serial module (QSM) 82 for later downloading to the memory 68 as the QSM 82 fills up. In an embodiment, there may be multiple parallel paths of separate amplifier, filter, and A/D converters for multiple light wavelengths or spectra received, and/or for phase data generated by the phase detector 58. In one embodiment, a signal from the phase detector 58 may be processed in any suitable manner, and may be sent through a different data path than the signal from the detector 54, which may be configured to detect amplitude of the photon density waves. The received optical signal may be converted into an electrical signal at the detector 54. The electrical signal may then be amplified by the amplifier 72 and sent to a frequency mixer or analog multiplier (e.g., analog multiplier 76) to generate a signal that is proportional to a phase difference between a reference oscillator (not shown) and the received signal. Similarly, the AC and DC amplitudes of the received signal may be determined with peak detection circuits and low pass filters (e.g., filter 78).
As illustrated in
In the illustrated embodiment, the modulator 84 is disposed in the monitor 12. However, in some embodiments the modulation function may be performed by a modulator disposed within the sensor 14. Indeed, it should be noted that in some embodiments, the features related to modulating and detecting the phase of the emitted light waves may be arranged within the system 10 to avoid potential interference. For example, high frequency modulation and detection features may be co-located within the sensor 14 to reduce the distance traveled by the signals, and, thus, reduce potential interference. Indeed, in a specific example, the sensor 14 may include a commercially available chip set for phase measurement and commonly available drive circuits (e.g., DVD R/W driver circuits) for high frequency modulation. Examples of such devices may include the AD8302 available from Analog Devices™ and the LMH6525 available from National Semiconductor™. In other embodiments the LDs 56 may be positioned within the monitor 12 and light may be transmitted from the LDs 56 in the monitor 12 to the sensor 14 via fiber optics to reduce potential interference.
Regardless of the modulator's location, in contrast to traditional pulse oximetry, which conducts measurements at sufficiently low frequencies (e.g., 1.5 KHz) to be considered DC, the modulator 84 may be configured to modulate the LDs 56 at sufficiently high frequencies (e.g., approximately 50 MHz to 3.0 GHz) to cause resolvable photon density waves to propagate through the tissue 52. In some embodiments, the modulator 84 may be configured to sweep a range from 50 MHz to 2.4 GHz. In some embodiments, the modulator 84 may be configured to modulate between 100 MHz and 1 GHz or to sweep a range from 100 MHz to 1 GHz. Thus, present embodiments operate at much higher frequencies than the traditional pulse oximetry sampling frequency of 1 sample every 67 microseconds.
In some embodiments, for continuous modulation of the LDs 56, resolvable amplitude and phase relationships of the photon density waves may be established at various positions from the emitter along the tissue bed 52. By modulating the light emitters at sufficiently high frequencies, the wavelengths of photon density waves may be shorter than the average distance required for light to be absorbed. Thus, the phase changes in the photon density waves can be attributed predominantly to scattering and not absorption. Further, in view of this, it can be determined that detected phase changes correspond to a number of scattering particles or volume change in the probed medium. The frequency of the photon density waves is essentially locked to the initial light source input and the phase change is essentially locked to arterial pulsation and the introduction of scattering particles. Indeed, the variation in AC scattering to DC scattering measured by phase offset may yield information about the total arteriole volume probed.
For a modulation frequency where the product of the frequency and the mean time between absorption events is much larger than 1, the change in phase between two points located a distance r from each other on a tissue bed may be given by the relation.
where c is the speed of light, ω is the angular frequency of modulation, and μs′ is the reduced scattering coefficient. The reduced scattering coefficient for a tissue bed is comprised of both blood and surrounding tissue components. It can be written as,
μs′total=Vbloodμs′blood+Vtissueμs′tissue.
The time varying component of this equation at a single wavelength will generally be only the portion due to arterial blood. The time varying component of this equation at a second wavelength will allow for the deconvolution of the scattering coefficient. The scattering coefficient for blood is related to the hematocrit (HCT) through the relation,
μs′blood=σs(1−g)(HCT/Vi(1−HCT)(1.4−HCT),
where g is the anisotropy factor, σ is the scattering cross section of an erythrocyte, Vi is the volume of an erythrocyte and HCT is the hematocrit.
Accordingly, when the modulator 84 operates at a high enough frequency, measured phase changes in the photon density waves may be utilized to calculate a number of scattering particles in the observed volume. For example, the monitor 12 may be configured to receive phase shift and/or amplitude data from the sensor 14 and calculate a value related to a quantity of scattering particles in the probed tissue for display on the monitor 12. Specifically, the monitor 12 may include instructions or an algorithm stored on the memory 68 and configured to perform such calculations.
As an example of the correlation of phase change measurements of photon density waves modulated at high frequency to a number of scattering particles in the probed medium,
Scattering may be quantified based on phase change. Specifically, as set forth above, a modulation frequency where the product of the frequency and the mean time between absorption events is much larger than 1, the change in phase between two points may be given by the relation,
Changes in phase due to arterial pulsation may be directly related to the change in scattering coefficient of the medium which is due to the change in the concentration of the number of erythrocytes. It should be noted that a second method for correlating the scattering changes from the phase could involve a calibration curve determined from tissue phantoms or clinical data.
In the illustrated embodiment, the control signal 200 is representative of dark intervals 202, intervals of power 204 being supplied to a red LD, and intervals of power 206 being supplied to an IR LD over time. Further, the control signal 200 has a period designated by reference number 208. This period 208 may be adjusted such that each of the LDs 56 may be modulated with a desired frequency (e.g., approximately 100-1000 MHz) to generate photon density waves. Such adjustments to the modulation frequency may facilitate detection of phase shifts in the photon density waves, and, thus, variations in scattering based on such phase shifts. As may be appreciated by those of ordinary skill in the art, the control signal 200 may be adjusted or modified for different scenarios. For example, the control signal 200 may be adjusted to be generally sinusoidal, adjusted to include various intensity levels, and so forth. The sinusoidal nature of the wave may be controlled by a wave generator and the intensity levels may be adjusted by providing more power and/or by reducing dark intervals and increasing the length of time that light is emitted.
As indicated above, the phase of the photon density waves may be sensitive to changes in the scattering coefficient, while the amplitude of the photon density waves may be sensitive to the concentration of absorbers in the medium. Specifically, with regard to amplitude measurements, the AC amplitude and DC amplitude may yield information about absorption in the volume. Thus, detection of amplitude changes in the photon density waves may be utilized to calculate absorber concentration values in the observed medium, such as blood oxygen saturation values. Such calculations may be made using the standard ratio of ratios (i.e., ratrat) technique for the constant and modulated values of the photon density wave amplitudes at two wavelengths. Once the ratio of ratios values is obtained, it may be mapped to the saturation from clinical calibration curves.
With regard to phase shift measurements, when the wavelengths of the photon density waves get below that of the mean absorption distance, the phase becomes almost exclusively a function of the scattering coefficient. While dependent upon the tissue bed being probed, this is generally believed to occur at a modulation frequency in the range of approximately 500 MHz. Thus, the phase shift measurement may yield information about the number of erythrocytes or red blood cells in the local probed volume. The HCT discussed above is proportional to the number of erythrocytes. Accordingly, by sweeping frequencies, a multi-parameter output may be obtained that relates to standard pulse oximetry measurements as well as the puddle hematorcit.
The amplitude and phase at a given frequency may be proportional to the scattering and absorption coefficient at a given wavelength until the product of the frequency and the mean time between absorption events is much larger than 1. When the product of the frequency and the mean time between absorption events is much larger than 1, the amplitude is a function of the absorption and phase is only a function of the scattering. Thus, a frequency sweep may be used to reduce the error in the determination of a single value of reduced scattering coefficient for the blood and a single value of absorption coefficient. Indeed, in some embodiments, the amplitude and phase information may be utilized together to yield a value of total hemoglobin per unit volume.
In some embodiments, by modulating the light sources at a sufficient frequency, and, thus, facilitating a detectable phase shift that corresponds to scattering particles, present embodiments may provide an extra degree of certainty for blood flow parameter measurements. Indeed, the detected amplitude for the photon density waves may be utilized to calculate traditional pulse oximetry information and the phase may be utilized to confirm that such values are correct (e.g., within a certain range of error). For example, the amplitude information may be utilized to calculate a blood oxygen saturation (SpO2) value and empirical data may indicate that a particular SpO2 value should correspond to a particular phase variation at a given frequency. In other words, there may be a certain phase change that should accompany a given increase in absorber observed as a change in amplitude. Various algorithms (e.g., learning based algorithms such as support vector machines, cluster analysis, neural networks, and PCA) based on the measured phase shift and amplitude change may be compared to determine if the amplitude shift and phase shift correlate to a known SpO2. If both the measured amplitude shift and phase shift correlate to a known SpO2, the measured SpO2 value may be deemed appropriate and displayed or utilized as a correct SpO2 value. Alternatively, if the measured amplitude shift and phase shift do not agree, the calculated SpO2 value may be identified as being corrupt or including too much noise and, thus, be discarded.
In some embodiments, as illustrated by
In other embodiments utilizing multiple emitters, the interference of photon density waves may facilitate sweeping photon density waves through a probed volume by changing the relative phase between the emitters. For example, such techniques may be utilized to establish a “phased array” of photon density waves for use in pulse oximetry and hemometry techniques. Indeed, such a “phased array” technique may facilitate identification of regions rich with pulsatile signals in the probed tissue and/or calibration of a sensor through the interference of photon density waves. For example, the phases of individual waves may be controlled to determine the intensity profile within the medium.
It may be desirable to detect regions rich with pulsatile signals to facilitate obtaining a strong pulsatile signal. For example, it may be desirable to focus on a specific location in tissue that includes an artery or even a specific portion of the artery. The transmission mode arrangement may facilitate access to such specific locations by enabling deep penetration. Periodic sweeps may be performed to insure that the focus remains on the pulsation-rich regions. Further, such a technique may define an adaptive measurement system that may be utilized to identify regions of low saturation and/or regions in the probed tissue where blockage may result in anemic conditions. Additionally, it is believed that the use of multiple emitters may facilitate adaptation of the sensor to different physiological variations between patients, such as different skin and/or tissue characteristics.
The inclusion of multiple detectors around a tissue bed may facilitate detection of and/or compensation for a variety of noise artifacts that typically plague existing pulse oximetry technologies. Indeed, for a given wavelength, a time-varying phase and amplitude relation between multiple detectors may be established which is correlated to arterial pulse. The phase and amplitude information may form a phase space that yields a bounded parameter space for a single wavelength that contains physiological measurements. Noise artifacts will typically lie outside of this bounded area, as will be discussed in further detail below. Further, the addition of a second wavelength may facilitate formation of a 4-dimensional physiological measurement space that facilitates noise artifact reduction due to constraints of decision planes in the hyperspace. Correlated phase and amplitude changes for a single wavelength are bounded by physiological parameters such as arteriole density, realistic hematocrit numbers, and so forth. At a single wavelength, these bounds result in bounds on the detected amplitude and phase in a 2D space. These same bounds are applicable for a second wavelength. The 4 factor correlation (phase(wavelength1), phase wavelength2), amplitude(wavelength1), amplitude(wavelength2)) is bounded by physiological factors in a linked 4D space. The bounds can be drawn as hyperplanes in that space. For example, cluster analysis, Neural Networks, and partial least squares (PLS) algorithms may be used to generate the decision planes and compensate for a variety of noise artifact.
In some embodiments, and as an example,
This application is a continuation-in-part of U.S. patent application Ser. No. 12/241,160, which was filed on Sep. 30, 2008, and is hereby incorporated by reference in its entirety for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
3638640 | Shaw | Feb 1972 | A |
4223680 | Jöbsis | Sep 1980 | A |
4281645 | Jöbsis | Aug 1981 | A |
4321930 | Jöbsis et al. | Mar 1982 | A |
4714341 | Hamaguri et al. | Dec 1987 | A |
4805623 | Jöbsis | Feb 1989 | A |
4807631 | Hersh et al. | Feb 1989 | A |
4911167 | Corenman et al. | Mar 1990 | A |
4913150 | Cheung et al. | Apr 1990 | A |
4936679 | Mersch | Jun 1990 | A |
4938218 | Goodman et al. | Jul 1990 | A |
4971062 | Hasebe et al. | Nov 1990 | A |
4972331 | Chance | Nov 1990 | A |
4974591 | Awazu et al. | Dec 1990 | A |
5028787 | Rosenthal et al. | Jul 1991 | A |
5065749 | Hasebe et al. | Nov 1991 | A |
5084327 | Stengel | Jan 1992 | A |
5088493 | Giannini et al. | Feb 1992 | A |
5119815 | Chance | Jun 1992 | A |
5122974 | Chance | Jun 1992 | A |
5167230 | Chance | Dec 1992 | A |
5187672 | Chance et al. | Feb 1993 | A |
5190038 | Polson et al. | Mar 1993 | A |
5246003 | DeLonzor | Sep 1993 | A |
5247931 | Norwood | Sep 1993 | A |
5263244 | Centa et al. | Nov 1993 | A |
5275159 | Griebel | Jan 1994 | A |
5279295 | Martens et al. | Jan 1994 | A |
5297548 | Pologe | Mar 1994 | A |
5355880 | Thomas et al. | Oct 1994 | A |
5372136 | Steuer et al. | Dec 1994 | A |
5385143 | Aoyagi | Jan 1995 | A |
5390670 | Centa et al. | Feb 1995 | A |
5413099 | Schmidt et al. | May 1995 | A |
5469845 | DeLonzor et al. | Nov 1995 | A |
5482036 | Diab et al. | Jan 1996 | A |
5483646 | Uchikoga | Jan 1996 | A |
5497769 | Gratton et al. | Mar 1996 | A |
5553614 | Chance | Sep 1996 | A |
5555885 | Chance | Sep 1996 | A |
5564417 | Chance | Oct 1996 | A |
5575285 | Takanashi et al. | Nov 1996 | A |
5611337 | Bukta | Mar 1997 | A |
5630413 | Thomas et al. | May 1997 | A |
5645059 | Fein et al. | Jul 1997 | A |
5645060 | Yorkey | Jul 1997 | A |
5680857 | Pelikan et al. | Oct 1997 | A |
5692503 | Kuenstner | Dec 1997 | A |
5730124 | Yamauchi | Mar 1998 | A |
5758644 | Diab et al. | Jun 1998 | A |
5779631 | Chance | Jul 1998 | A |
5782757 | Diab et al. | Jul 1998 | A |
5786592 | Hök | Jul 1998 | A |
5830136 | DeLonzor et al. | Nov 1998 | A |
5830139 | Abreu | Nov 1998 | A |
5831598 | Kauffert et al. | Nov 1998 | A |
5842981 | Larsen et al. | Dec 1998 | A |
5871442 | Madarasz et al. | Feb 1999 | A |
5873821 | Chance et al. | Feb 1999 | A |
5920263 | Huttenhoff et al. | Jul 1999 | A |
5995855 | Kiani et al. | Nov 1999 | A |
5995856 | Mannheimer et al. | Nov 1999 | A |
5995859 | Takahashi | Nov 1999 | A |
6011986 | Diab et al. | Jan 2000 | A |
6058324 | Chance | May 2000 | A |
6064898 | Aldrich | May 2000 | A |
6081742 | Amano et al. | Jun 2000 | A |
6088607 | Diab et al. | Jul 2000 | A |
6120460 | Abreu | Sep 2000 | A |
6134460 | Chance | Oct 2000 | A |
6150951 | Olejniczak | Nov 2000 | A |
6154667 | Miura et al. | Nov 2000 | A |
6163715 | Larsen et al. | Dec 2000 | A |
6181958 | Steuer et al. | Jan 2001 | B1 |
6181959 | Schöllermann et al. | Jan 2001 | B1 |
6192261 | Gratton et al. | Feb 2001 | B1 |
6230035 | Aoyagi et al. | May 2001 | B1 |
6266546 | Steuer et al. | Jul 2001 | B1 |
6285895 | Ristolainen et al. | Sep 2001 | B1 |
6312393 | Abreu | Nov 2001 | B1 |
6322515 | Goor et al. | Nov 2001 | B1 |
6352502 | Chaiken et al. | Mar 2002 | B1 |
6353750 | Kimura et al. | Mar 2002 | B1 |
6397091 | Diab et al. | May 2002 | B2 |
6415236 | Kobayashi et al. | Jul 2002 | B2 |
6419671 | Lemberg | Jul 2002 | B1 |
6438399 | Kurth | Aug 2002 | B1 |
6461305 | Schnall | Oct 2002 | B1 |
6466809 | Riley | Oct 2002 | B1 |
6487439 | Skladnev et al. | Nov 2002 | B1 |
6501974 | Huiku | Dec 2002 | B2 |
6501975 | Diab et al. | Dec 2002 | B2 |
6516209 | Cheng et al. | Feb 2003 | B2 |
6526301 | Larsen et al. | Feb 2003 | B2 |
6544193 | Abreu | Apr 2003 | B2 |
6546267 | Sugiura et al. | Apr 2003 | B1 |
6549795 | Chance | Apr 2003 | B1 |
6580086 | Schulz et al. | Jun 2003 | B1 |
6591122 | Schmitt | Jul 2003 | B2 |
6594513 | Jobsis et al. | Jul 2003 | B1 |
6606509 | Schmitt | Aug 2003 | B2 |
6606511 | Ali et al. | Aug 2003 | B1 |
6615064 | Aldrich | Sep 2003 | B1 |
6618042 | Powell | Sep 2003 | B1 |
6622095 | Kobayashi et al. | Sep 2003 | B2 |
6654621 | Palatnik et al. | Nov 2003 | B2 |
6654624 | Diab et al. | Nov 2003 | B2 |
6658276 | Kianl et al. | Dec 2003 | B2 |
6658277 | Wasserman | Dec 2003 | B2 |
6662030 | Khalil et al. | Dec 2003 | B2 |
6668183 | Hicks et al. | Dec 2003 | B2 |
6671526 | Aoyagi et al. | Dec 2003 | B1 |
6671528 | Steuer et al. | Dec 2003 | B2 |
6678543 | Diab et al. | Jan 2004 | B2 |
6684090 | Ali et al. | Jan 2004 | B2 |
6690958 | Walker et al. | Feb 2004 | B1 |
6697658 | Al-Ali | Feb 2004 | B2 |
6708048 | Chance | Mar 2004 | B1 |
6711424 | Fine et al. | Mar 2004 | B1 |
6711425 | Reuss | Mar 2004 | B1 |
6714245 | Ono | Mar 2004 | B1 |
6731274 | Powell | May 2004 | B2 |
6785568 | Chance | Aug 2004 | B2 |
6793654 | Lemberg | Sep 2004 | B2 |
6801648 | Cheng | Oct 2004 | B2 |
6801797 | Mannheimer et al. | Oct 2004 | B2 |
6801798 | Geddes et al. | Oct 2004 | B2 |
6801799 | Mendelson | Oct 2004 | B2 |
6829496 | Nagai et al. | Dec 2004 | B2 |
6850053 | Daalmans et al. | Feb 2005 | B2 |
6859658 | Krug | Feb 2005 | B1 |
6863652 | Huang et al. | Mar 2005 | B2 |
6873865 | Steuer et al. | Mar 2005 | B2 |
6889153 | Dietiker | May 2005 | B2 |
6898451 | Wuori | May 2005 | B2 |
6939307 | Dunlop | Sep 2005 | B1 |
6947780 | Scharf | Sep 2005 | B2 |
6949081 | Chance | Sep 2005 | B1 |
6961598 | Diab | Nov 2005 | B2 |
6983178 | Fine et al. | Jan 2006 | B2 |
6993371 | Kiani et al. | Jan 2006 | B2 |
6996427 | Ali et al. | Feb 2006 | B2 |
7006676 | Zeylikovich et al. | Feb 2006 | B1 |
7024235 | Melker et al. | Apr 2006 | B2 |
7027849 | Al-Ali | Apr 2006 | B2 |
7030749 | Al-Ali | Apr 2006 | B2 |
7035697 | Brown | Apr 2006 | B1 |
7047056 | Hannula et al. | May 2006 | B2 |
7090648 | Sackner et al. | Aug 2006 | B2 |
7127278 | Melker et al. | Oct 2006 | B2 |
7162306 | Caby et al. | Jan 2007 | B2 |
7164938 | Geddes et al. | Jan 2007 | B2 |
7209775 | Bae et al. | Apr 2007 | B2 |
7236811 | Schmitt | Jun 2007 | B2 |
7263395 | Chan et al. | Aug 2007 | B2 |
7272426 | Schmid | Sep 2007 | B2 |
7330746 | Demuth et al. | Feb 2008 | B2 |
7373193 | Al-Ali et al. | May 2008 | B2 |
7375347 | Colvin et al. | May 2008 | B2 |
7378954 | Wendt | May 2008 | B2 |
20010005773 | Larsen et al. | Jun 2001 | A1 |
20010020122 | Steuer et al. | Sep 2001 | A1 |
20010039376 | Steuer et al. | Nov 2001 | A1 |
20010044700 | Kobayashi et al. | Nov 2001 | A1 |
20020026106 | Khalil et al. | Feb 2002 | A1 |
20020035318 | Mannheimer et al. | Mar 2002 | A1 |
20020038079 | Steuer et al. | Mar 2002 | A1 |
20020042558 | Mendelson | Apr 2002 | A1 |
20020049389 | Abreu | Apr 2002 | A1 |
20020062071 | Diab et al. | May 2002 | A1 |
20020111748 | Kobayashi et al. | Aug 2002 | A1 |
20020133068 | Huiku | Sep 2002 | A1 |
20020156354 | Larson | Oct 2002 | A1 |
20020161287 | Schmitt | Oct 2002 | A1 |
20020161290 | Chance | Oct 2002 | A1 |
20020165439 | Schmitt | Nov 2002 | A1 |
20020198443 | Ting | Dec 2002 | A1 |
20030023140 | Chance | Jan 2003 | A1 |
20030055324 | Wasserman | Mar 2003 | A1 |
20030060693 | Monfre et al. | Mar 2003 | A1 |
20030139687 | Abreu | Jul 2003 | A1 |
20030144584 | Mendelson | Jul 2003 | A1 |
20030220548 | Schmitt | Nov 2003 | A1 |
20030220576 | Diab | Nov 2003 | A1 |
20040010188 | Wasserman | Jan 2004 | A1 |
20040054270 | Pewzner et al. | Mar 2004 | A1 |
20040087846 | Wasserman | May 2004 | A1 |
20040107065 | Al-Ali | Jun 2004 | A1 |
20040127779 | Steuer et al. | Jul 2004 | A1 |
20040171920 | Mannheimer et al. | Sep 2004 | A1 |
20040176670 | Takamura et al. | Sep 2004 | A1 |
20040176671 | Fine et al. | Sep 2004 | A1 |
20040230106 | Schmitt et al. | Nov 2004 | A1 |
20050080323 | Kato | Apr 2005 | A1 |
20050101850 | Parker | May 2005 | A1 |
20050113651 | Wood et al. | May 2005 | A1 |
20050113656 | Chance | May 2005 | A1 |
20050168722 | Forstner et al. | Aug 2005 | A1 |
20050177034 | Beaumont | Aug 2005 | A1 |
20050192488 | Bryenton et al. | Sep 2005 | A1 |
20050197583 | Chance | Sep 2005 | A1 |
20050203357 | Debreczeny et al. | Sep 2005 | A1 |
20050209516 | Fraden | Sep 2005 | A1 |
20050228248 | Dietiker | Oct 2005 | A1 |
20050267346 | Faber et al. | Dec 2005 | A1 |
20050283059 | Iyer et al. | Dec 2005 | A1 |
20060009688 | Lamego et al. | Jan 2006 | A1 |
20060015021 | Cheng | Jan 2006 | A1 |
20060020181 | Schmitt | Jan 2006 | A1 |
20060030763 | Mannheimer et al. | Feb 2006 | A1 |
20060052680 | Diab | Mar 2006 | A1 |
20060058595 | Herrmann | Mar 2006 | A1 |
20060058683 | Chance | Mar 2006 | A1 |
20060063995 | Yodh et al. | Mar 2006 | A1 |
20060064024 | Schnall | Mar 2006 | A1 |
20060122475 | Balberg et al. | Jun 2006 | A1 |
20060129037 | Kaufman et al. | Jun 2006 | A1 |
20060129038 | Zelenchuk et al. | Jun 2006 | A1 |
20060195028 | Hannula et al. | Aug 2006 | A1 |
20060224058 | Mannheimer | Oct 2006 | A1 |
20060247501 | Ali | Nov 2006 | A1 |
20060247506 | Balberg et al. | Nov 2006 | A1 |
20060258921 | Addison et al. | Nov 2006 | A1 |
20070093702 | Yu et al. | Apr 2007 | A1 |
20080139908 | Kurth | Jun 2008 | A1 |
20080200823 | Cho et al. | Aug 2008 | A1 |
20080312533 | Balberg et al. | Dec 2008 | A1 |
Number | Date | Country |
---|---|---|
732799 | May 2001 | AU |
69123448 | May 1997 | DE |
19640807 | Sep 1997 | DE |
0194105 | Sep 1986 | EP |
0826958 | Mar 1998 | EP |
3124073 | May 1991 | JP |
3170866 | Jul 1991 | JP |
3238813 | Oct 1991 | JP |
4191642 | Jul 1992 | JP |
4332536 | Nov 1992 | JP |
5049624 | Mar 1993 | JP |
7124138 | May 1995 | JP |
10216115 | Sep 1998 | JP |
11019074 | Jan 1999 | JP |
2003194714 | Jul 2003 | JP |
2003210438 | Jul 2003 | JP |
2003275192 | Sep 2003 | JP |
2003339678 | Dec 2003 | JP |
2004008572 | Jan 2004 | JP |
2004194908 | Jul 2004 | JP |
2004202190 | Jul 2004 | JP |
2004248819 | Sep 2004 | JP |
2004290544 | Oct 2004 | JP |
2004290545 | Oct 2004 | JP |
WO9101678 | Feb 1991 | WO |
WO9200513 | Jan 1992 | WO |
WO9221281 | Dec 1992 | WO |
WO9309711 | May 1993 | WO |
WO9313706 | Jul 1993 | WO |
WO9316629 | Sep 1993 | WO |
WO9403102 | Feb 1994 | WO |
WO9512349 | May 1995 | WO |
WO9749330 | Dec 1997 | WO |
WO9817174 | May 1998 | WO |
WO9842249 | Oct 1998 | WO |
WO9842251 | Oct 1998 | WO |
WO9843071 | Oct 1998 | WO |
WO9932030 | Jul 1999 | WO |
WO0021438 | Apr 2000 | WO |
WO0140776 | Jun 2001 | WO |
WO03077750 | Sep 2003 | WO |
WO 03102558 | Dec 2003 | WO |
WO2004010844 | Feb 2004 | WO |
WO2005009221 | Feb 2005 | WO |
WO2005064314 | Jul 2005 | WO |
WO2007051066 | May 2007 | WO |
WO 2010039418 | Apr 2010 | WO |
Entry |
---|
D.J. Pine, et al.; “Diffusing-Wave Spectroscopy,” The American Physical Society, vol. 60, No. 12, Mar. 1988, pp. 1134-1137. |
D.J. Pine, et al.; “Diffusing-wave spectroscopy: dynamic light scattering in the multiple scattering limit,” J. Phys. France, vol. 51, Sep. 1990, pp. 2101-2127. |
X.L. Wu, et al.; “Diffusing-wave spectroscopy in a shear flow,” J. Opt. Soc. Am. B., vol. 7, No. 1, Jan. 1990, pp. 15-20. |
J.M. Schmitt, et al.; “Interference of diffusive light waves,” J. Opt. Soc. Am. A., vol. 9, No. 10 (Oct. 1992), pp. 1832-1843. |
Aoyagi, T., et al.; “Analysis of Motion Artifacts in Pulse Oximetry,” Japanese Society ME, vol. 42, p. 20 (1993) (Article in Japanese—contains English summary of article). |
D.A. Weitz, et al.; “Diffusing-Wave Spectroscopy: The Technique and Some Applications,” Physica Scripta, vol. T49, 1993, pp. 610-621. |
Barreto, A.B., et al.; “Adaptive Cancelation of Motion artifact in Photoplethysmographic Blood Volume Pulse Measurements for Exercise Evaluation,” IEEE-EMBC and CMBEC—Theme 4: Signal Processing, pp. 983-984 (1995). |
Vincente, L.M., et al.; “Adaptive Pre-Processing of Photoplethysmographic Blood Volume Pulse Measurements,” pp. 114-117 (1996). |
Plummer, John L., et al.; “Identification of Movement Artifact by the Nellcor N-200 and N-3000 Pulse Oximeters,” Journal of clinical Monitoring, vol. 13, pp. 109-113 (1997). |
Barnum, P.T., et al.; “Novel Pulse Oximetry Technology Capable of Reliable Bradycardia Monitoring in the Neonate,” Respiratory Care, vol. 42, No. 1, p. 1072 (Nov. 1997). |
Poets, C. F., et al.; “Detection of movement artifact in recorded pulse oximeter saturation,” Eur. J. Pediatr.; vol. 156, pp. 808-811 (1997). |
Masin, Donald I., et al.; “Fetal Transmission Pulse Oximetry,” Proceedings 19th International Conference IEEE/EMBS, Oct. 30-Nov. 2, 1997; pp. 2326-2329. |
Nijland, Roel, et al.; “Validation of Reflectance Pulse Oximetry: An Evaluation of a new Sensor in Piglets,” Journal of Clinical Monitoring, vol. 13, pp. 43-49 (1997). |
Nogawa, Masamichi, et al.; “A New Hybrid Reflectance Optical Pulse Oximetry Sensor for Lower Oxygen Saturation Measurement and for Broader Clinical Application,” SPIE, vol. 2976, pp. 78-87 (1997). |
Mannheimer, Paul D., et al.; “Wavelength Selection for Low-Saturation Pulse Oximetry,” IEEE Transactions on Biomedical Engineering, vol. 44, No. 3, pp. 148-158 (Mar. 1997). |
Buschman, J.P., et al.; “Principles and Problems of Calibration of Fetal Oximeters,” Biomedizinische Technik, vol. 42, pp. 265-266 (1997). |
Leahy, Martin J., et al.; “Sensor Validation in Biomedical Applications,” IFAC Modelling and Control in Biomedical Systems, Warwick, UK; pp. 221-226 (1997). |
Barreto, Armando B., et al.; “Adaptive LMS Delay Measurement in dual Blood Volume Pulse Signals for Non-Invasive Monitoring,” IEEE, pp. 117-120 (1997). |
East, Christine E., et al.; “Fetal Oxygen Saturation and Uterine Contractions During Labor,” American Journal of Perinatology, vol. 15, No. 6, pp. 345-349 (Jun. 1998). |
Hayes, Matthew J., et al.; “Quantitative evaluation of photoplethysmographic artifact reduction for pulse oximetry,” SPIE, vol. 3570, pp. 138-147 (Sep. 1998). |
Edrich, Thomas, et al.; “Can the Blood Content of the Tissues be Determined Optically During Pulse Oximetry Without Knowledge of the Oxygen Saturation?—An In-Vitro Investigation,” Proceedings of the 20th Annual International conference of the IEEE Engie in Medicine and Biology Society, vol. 20, No. 6, p. 3072-3075, 1998. |
Hayes, Matthew J., et al.; “Artifact reduction in photoplethysmography,” Applied Optics, vol. 37, No. 31, pp. 7437-7446 (Nov. 1998). |
S.E. Skipetrov, et al.; “Diffusing-wave spectroscopy in randomly inhomogeneous media with spatially localized scatterer flows,” Journal of Experimental and Theoretical Physics, vol. 86, No. 4, Apr. 1998, pp. 661-665. |
Such, Hans Olaf; “Optoelectronic Non-invasive Vascular Diagnostics Using multiple Wavelength and Imaging Approach,” Dissertation, (1998). |
Lutter, N., et al.; “Comparison of Different Evaluation Methods for a Multi-wavelength Pulse Oximeter,” Biomedizinische Technik, vol. 43, (1998). |
Z.L. Wu, et al.; “Laser modulated scattering as a nondestructive evaluation tool for defect inspection in optical materials for high power laser applications,” Optics Express, vol. 3, No. 10; Nov. 1998, pp. 376-383. |
Todd, Bryan, et al.; “The Identification of Peaks in Physiological Signals,” Computers and Biomedical Research, vol. 32, pp. 322-335 (1999). |
G. Popescu, et al.; “Optical path-length spectroscopy of wave propagation in random media,” Optics Letters, vol. 24, No. 7, Apr. 1999, pp. 442-444. |
Rhee, Sokwoo, et al.; “Design of a Artifact-Free Wearable Plethysmographic Sensor,” Proceedings of the First joint BMES/EMBS Conference, Oct. 13-16, 1999, Altanta, Georgia, p. 786. |
Rheineck-Leyssius, Aart t., et al.; “Advanced Pulse Oximeter Signal Processing Technology Compared to Simple Averaging: I. Effect on Frequency of Alarms in the Operating Room,” Journal of clinical Anestesia, vol. 11, pp. 192-195 (1999). |
Kaestle, S.; “An Algorithm for Reliable Processing of Pulse Oximetry Signals Under strong Noise Conditions,” Dissertation Book, Lubeck University, Germany (1999). |
Seelbach-Göbel, Birgit, et al.; “The prediction of fetal acidosis by means of intrapartum fetal pulse oximetry,” Am J. Obstet. Gynecol., vol. 180, No. 1, Part 1, pp. 73-81 (1999). |
Goldman, Julian M.; “Masimo Signal Extraction Pulse Oximetry,” Journal of Clinical Monitoring and Computing, vol. 16, pp. 475-483 (2000). |
Coetzee, Frans M.; “Noise-Resistant Pulse Oximetry Using a Synthetic Reference Signal,” IEEE Transactions on Biomedical Engineering, vol. 47, No. 8, Aug. 2000, pp. 1018-1026. |
Al. N. Korolevich, et al.: “Experimental study of the potential use of diffusing wave spectroscopy to investigate the structural characteristics of blood under multiple scattering,” Bioelectrochemistry, vol. 52, 2000, pp. 223-227. |
V. Ntziachristos, et al.; “Oximetry based on diffuse photon density wave differentials,” Am. Assoc. Phys. Med., vol. 27, No. 2, Feb. 2000, pp. 410-521. |
Yao, Jianchu, et al.; “Design of a Plug-and-Play Pulse Oximeter,” Proceedings of the Second Joint EMBS/BMES Conference, Houston, Texas, Oct. 23-26, 2002; pp. 1752-1753. |
Kaestle, S.; “Determining Artefact Sensitivity of New Pulse Oximeters in Laboratory Using Signals Obtained from Patient,” Biomedizinische Technik, vol. 45 (2000). |
Cysewska-Sobusaik, Anna; “Metrological Problems With noninvasive Transillumination of Living Tissues,” Proceedings of SPIE, vol. 4515, pp. 15-24 (2001). |
Belal, Suliman Yousef, et al.; “A fuzzy system for detecting distorted plethysmogram pulses in neonates and paediatric patients,” Physiol. Meas., vol. 22, pp. 397-412 (2001). |
Hayes, Matthew J., et al.; “A New Method for Pulse Oximetry Possessing Inherent Insensitivity to Artifact,” IEEE Transactions on Biomedical Engineering, vol. 48, No. 4, pp. 452-461 (Apr. 2001). |
Maletras, Francois-Xavier, et al.; “Construction and calibration of a new design of Fiber Optic Respiratory Plethysmograph (FORP),” Optomechanical Design and Engineering, Proceedings of SPIE, vol. 4444, pp. 285-293 (2001). |
Gehring, Harmut, et al.; “The Effects of Motion Artifact and Low Perfusion on the Performance of a New Generation of Pulse Oximeters in Volunteers Undergoing Hypoxemia,” Respiratory Care, Vo. 47, No. 1, pp. 48-60 (Jan. 2002). |
Jopling, Michae W., et al.; “Issues in the Laboratory Evaluation of Pulse Oximeter Performance,” Anesth Analg, vol. 94, pp. S62-S68 (2002). |
Lutter, N., et al.; “Accuracy of Noninvasive Continuous Blood Pressure; Measurement Utilising the Pulse Transit Time,” Journal of clinical Monitoring and Computing, vol. 17, Nos. 7-8, pp. 469 (2002). |
Gostt, R., et al.; “Pulse Oximetry Artifact Recognition Algorithm for Computerized Anaesthetic Records,” Journal of Clinical Monitoring and Computing Abstracts, p. 471 (2002). |
Chan, K.W., et al.; “17.3: Adaptive Reduction of Motion Artifact from Photoplethysmographic Recordings using a Variable Step-Size LMS Filter,” IEEE, pp. 1343-1346 (2002). |
Yamaya, Yoshiki, et al.; “Validity of pulse oximetry during maximal exercise in normoxia, hypoxia, and hyperoxia,” J. Appl. Physiol., vol. 92, pp. 162-168 (2002). |
Relente, A.R., et al.; “Characterization and Adaptive Filtering of Motion Artifacts in Pulse Oximetry using Accelerometers,” Proceedings of the Second joint EMBS/BMES Conference, Houston, Texas, Oct. 23-26, 2002; pp. 1769-1770. |
Yoon, Gilwon, et al.; Multiple diagnosis based on Photo-plethysmography: hematocrit, SpO2, pulse and respiration, Optics in Health Care and Biomedical optics: Diagnostics and Treatment; Proceedings of the SPIE, vol. 4916; pp. 185-188 (2002). |
Tremper, K.K.; “A Second Generation Technique for Evaluating Accuracy and Reliability of Second Generation Pulse Oximeters,” Journal of Clinical Monitoring and Computing, vol. 16, pp. 473-474 (2000). |
Lopez-Silva, Sonnia Maria Lopez, et al.; “Near-infrared transmittance pulse oximetry with laser diodes,” Journal of Biomedical Optics, vol. 8, No. 3, pp. 525-533 (Jul. 2003). |
Cyrill, D., et al.; “Adaptive Comb Filter for Quasi-Periodic Physiologic Signals,” Proceedings of the 25th Annual International Conference of the IEEE EMBS, Cancun, Mexico, Sep. 17-21, 2003; pp. 2439-2442. |
Stetson, Paul F.; “Determining Heart Rate from Noisey Pulse Oximeter Signals Using Fuzzy Logic,” The IEEE International Conference on Fuzzy Systems, St. Louis, Missouri, May 25-28, 2003; pp. 1053-1058. |
Aoyagi, Takuo; “Pulse oximetry: its invention, theory, and future,” Journal of Anesthesia, vol. 17, pp. 259-266 (2003). |
Lee, C.M., et al.; “Reduction of motion artifacts from photoplethysmographic recordings using wavelet denoising approach,” IEEE EMBS Asian-Pacific Conference on Biomedical Engineering, Oct. 20-22, 2003; pp. 194-195. |
A. Johansson; “Neural network for photoplethysmographic respiratory rate monitoring,” Medical & Biological Engineering & Computing, vol. 41, pp. 242-248 (2003). |
Lopez-Silva, S.M., et al.; “Transmittance Photoplethysmography and Pulse Oximetry With Near Infrared Laser Diodes,” IMTC 2004—Instrumentation and Measurement Technology Conference, Como, Italy, May 18-20, 2004; pp. 718-723. |
Addison, Paul S., et al.; “A novel time-frequency-based 3D Lissajous figure method and its application to the determination of oxygen saturation from the photoplethysmogram,” Institute of Physic Publishing, Meas. Sci. Technol., vol. 15, pp. L15-L18 (2004). |
Yao, Jianchu, et al.; “A Novel Algorithm to Separate Motion Artifacts from Photoplethysmographic Signals Obtained With a Reflectance Pulse Oximeter,” Proceedings of the 26th Annual International conference of the IEEE EMBS, San Francisco, California, Sep. 2004, pp. 2153-2156. |
Matsuzawa, Y., et al.; “Pulse Oximeter,” Home Care Medicine, pp. 42-45 (Jul. 2004); (Article in Japanese—contains English summary of article). |
Crespi, F., et al.; “Near infrared oxymeter prototype for non-invasive analysis of rat brain oxygenation,” Optical Sensing, Proceedings of SPIE, vol. 5459, pp. 38-45 (2004). |
Yan, Yong-sheng, et al.; “Reduction of motion artifact in pulse oximetry by smoothed pseudo Wigner-Ville distribution,” Journal of NeuroEngineering and Rehabilitation, vol. 2, No. 3 (9 pages) (Mar. 2005). |
F. Jaillon, et al.; “Diffusing-wave spectroscopy from head-like tissue phantoms: influence of a non-scattering layer,” Optics Express, vol. 14, No. 22; Oct. 2006, pp. 10181-10194. |
G. Dietsche, et al.; “Fiber-based multispeckle detection for time-resolved diffusing-wave spectroscopy: characterization and application to blood flow detection in deep tissue,” Applied Optics, vol. 46, No. 35; Dec. 2007, pp. 8506-8514. |
J. Huang, et al.; “Low Power Motion Tolerant Pulse Oximetry,” Abstracts, A7, p. S103. (undated). |
P. Lang, et al.; “Signal Identification and Quality Indicator™ for Motion Resistant Pulse Oximetry,” Abstracts, A10, p. S105. (undated). |
Hamilton, Patrick S., et al.; “Effect of Adaptive Motion-Artifact Reduction on QRS Detection,” Biomedical Instrumentation & Technology, pp. 197-202 (undated). |
Kim, J.M., et al.; “Signal Processing Using Fourier & Wavelet Transform,” pp. II-310-II-311 (undated). |
R. Neumann, et al.; “Fourier Artifact suppression Technology Provides Reliable SpO2,,” Abstracts, A11, p. S105. (undated). |
Odagiri, Y.; “Pulse Wave Measuring Device,” Micromechatronics, vol. 42, No. 3, pp. 6-11 (undated) (Article in Japanese—contains English summary of article). |
J.M. Tualle, et al.; “Time-Resolved Diffusing Wave Spectroscopy for selected photon paths beyond 300 transport mean free paths,” White Paper (undated). |
Yamazaki, Nakaji, et al.; “Motion Artifact Resistant Pulse Oximeter (Durapulse PA 2100),” Journal of Oral Cavity Medicine, vol. 69, No. 4, pp. 53 (date unknown) (Article in Japanese—contains English summary of article). |
International Search Report PCT/US2010/037571, 4 pages, mailed Dec. 17, 2010. |
Number | Date | Country | |
---|---|---|---|
20100081897 A1 | Apr 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12241160 | Sep 2008 | US |
Child | 12512127 | US |